Ernexa
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1035 Cambridge St 18A, Cambridge, Massac...Phone Number
(617) 798-6700Website
www.ernexatx.comRevenue
-Stock Symbol
ERNAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About Ernexa
Ernexa Therapeutics is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexas core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexas allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting. ERNA-101 is the Companys lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The Companys initial focus is to develop ERNA-101 for the treatment of ovarian cancer.Explore more
Ernexa Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ernexa your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Ernexa launches new products
Ernexa, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Ernexa recently announced quarterly report
Funding: Get notified immidiatlly once Ernexa has new funding data
Congratulate Masked Content for being promoted to Masked Content at Ernexa
Click to see if Ernexa had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Ernexa is spiking on competitors!
Check if Ernexa has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Ernexa as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Ernexa is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ernexa is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ernexa.
Ernexa financials insights
Gather financial insights about Ernexa, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$15.1M
Private Equity
$40.6M
2016
Multiple Rounds
$41.6M
2020
Debt
$150K
2021
Unspecified
$20M
Stock Offering
$40.7M
2026
Stock/Share Issuance
$10.5M
Ernexa Tech Stack
A closer look at the technologies used by Ernexa
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Funding
Funding
Earnings
Earnings, Finance
Project
Financial Planning, Corporate Strategy, Finance, Financial Strategy
Ernexa News & Media
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically "Cold" Tumors Into Targets for the Immune SystemThree Biotechs Deliver Catalysts to Watch
Today’s announcements from $NTHI, $ERNA, and $VIVS highlight three distinct pathways to potential value creation.Three Biotechs Deliver Catalysts to Watch
Today’s announcements from $NTHI, $ERNA, and $VIVS highlight three distinct pathways to potential value creation.Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Ernexa
Sign Up For FreeTo access detailed company insights
Ernexa Therapeutics is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexas core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexas allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatm... Read More
